Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henning Lauterbach

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Cancer Gene Therapy|April 28, 2026
Preclinical development of a mutant KRAS targeting therapeutic cancer vaccineCatarina Pinto, Romana Bischl, Lea Knezevic, et al.
Journal of Virology|March 30, 2004
Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1Henning Lauterbach, Kristen M Kerksiek, Dirk H Busch, et al.
Journal of Virology|October 10, 2014
Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responsesMichael Wolferstätter, Marc Schweneker, Michaela Späth, et al.
Journal for Immunotherapy of Cancer|February 13, 2021
Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memoryMaria Hinterberger, Raphael Giessel, Giovanna Fiore, et al.
Frontiers in Immunology|February 9, 2018
NLRC4 Inflammasome-Driven Immunogenicity of a Recombinant MVA Mucosal Vaccine Encoding FlagellinStephanie L Sanos, Ronny Kassub, Marco Testori, et al.
Oncoimmunology|June 24, 2025
The long-lasting expression of recombinant artLCMV following intraperitoneal administration exerts potent antitumor effects on tumor models of peritoneal carcinomatosisCelia Gomar, Aline Risson, Leire Arrizabalaga, et al.
Nature Communications|November 8, 2019
Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodiesJosé Medina-Echeverz, Maria Hinterberger, Marco Testori, et al.
Journal of Virology|March 24, 2017
Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like ParticlesMarc Schweneker, Andrea S Laimbacher, Gert Zimmer, et al.
Brain, Behavior, and Immunity|April 25, 2021
Type I interferon mediated induction of somatostatin leads to suppression of ghrelin and appetite thereby promoting viral immunity in miceSusanne Stutte, Janina Ruf, Ina Kugler, et al.
Frontiers in Oncology|November 1, 2021
Development and Characterization of a Novel Non-Lytic Cancer Immunotherapy Using a Recombinant Arenavirus Vector PlatformHenning Lauterbach, Sarah Schmidt, Kia Katchar, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Cancer Gene Therapy|April 28, 2026
Preclinical development of a mutant KRAS targeting therapeutic cancer vaccineCatarina Pinto, Romana Bischl, Lea Knezevic, et al.
Journal of Virology|March 30, 2004
Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1Henning Lauterbach, Kristen M Kerksiek, Dirk H Busch, et al.
Journal of Virology|October 10, 2014
Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responsesMichael Wolferstätter, Marc Schweneker, Michaela Späth, et al.
Journal for Immunotherapy of Cancer|February 13, 2021
Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memoryMaria Hinterberger, Raphael Giessel, Giovanna Fiore, et al.
Frontiers in Immunology|February 9, 2018
NLRC4 Inflammasome-Driven Immunogenicity of a Recombinant MVA Mucosal Vaccine Encoding FlagellinStephanie L Sanos, Ronny Kassub, Marco Testori, et al.
Oncoimmunology|June 24, 2025
The long-lasting expression of recombinant artLCMV following intraperitoneal administration exerts potent antitumor effects on tumor models of peritoneal carcinomatosisCelia Gomar, Aline Risson, Leire Arrizabalaga, et al.
Nature Communications|November 8, 2019
Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodiesJosé Medina-Echeverz, Maria Hinterberger, Marco Testori, et al.
Journal of Virology|March 24, 2017
Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like ParticlesMarc Schweneker, Andrea S Laimbacher, Gert Zimmer, et al.
Brain, Behavior, and Immunity|April 25, 2021
Type I interferon mediated induction of somatostatin leads to suppression of ghrelin and appetite thereby promoting viral immunity in miceSusanne Stutte, Janina Ruf, Ina Kugler, et al.
Frontiers in Oncology|November 1, 2021
Development and Characterization of a Novel Non-Lytic Cancer Immunotherapy Using a Recombinant Arenavirus Vector PlatformHenning Lauterbach, Sarah Schmidt, Kia Katchar, et al.
Pageof 4